Kiniksa preps BLA as Regeneron drug cruises to a PhIII win — shares soar

Kiniksa made a modest $5 million cash bet on Regeneron’s Arcalyst (rilonacept) back in 2017. The startup forged a pact to use the drug, which targets IL-1α and IL-1β, and see how it works against recurrent pericarditis, agreeing to split any profits to come while putting another $27 million in milestones up for grabs.